Related Experiment Video
Updated: Jul 2, 2025
02:47
Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
Published on: May 12, 2023
1.4K
RNA Therapeutics for the Cardiovascular System.
Victor J Dzau1,2, Conrad P Hodgkinson1
1Mandel Center for Hypertension and Atherosclerosis, and the Duke Cardiovascular Research Center, Duke University Medical Center, Durham, NC (V.J.D., C.P.H.).
Circulation
|February 26, 2024
Summary
RNA therapeutics show great promise for cardiovascular diseases, including hypertension and heart regeneration. Advances in messenger RNA (mRNA) and microRNA therapies offer new treatment avenues.
Area of Science:
- Cardiovascular Medicine
- Molecular Biology
- Genetics
Background:
- RNA therapeutics are emerging as a powerful tool for treating cardiovascular diseases, building on the success of mRNA vaccines.
- The diverse nature of RNA molecules allows for both gain- and loss-of-function applications in disease management.
Purpose of the Study:
- To provide a comprehensive overview of the current landscape of RNA-based therapies for cardiovascular diseases.
- To discuss the clinical development and potential of various RNA molecule types.
Main Methods:
- Review of existing literature on RNA therapeutics in cardiovascular medicine.
- Analysis of clinical trial data for RNA-based drugs, particularly for hypertension.
- Exploration of emergent RNA technologies like microRNAs and gene editing.
Main Results:
- Small interfering RNA (siRNA) drugs have shown efficacy in managing hypertension.
- Messenger RNA (mRNA) technology is being investigated for myocardial revascularization and protection.
- MicroRNAs and RNA-based gene editing show potential for cardiac regeneration and curing monogenic cardiovascular diseases.
Conclusions:
- RNA-based therapies represent a rapidly advancing field with significant potential for treating a wide range of cardiovascular conditions.
- Future developments in RNA technology promise novel therapeutic strategies for myocardial regeneration, disease management, and potentially permanent cures.
Related Concept Videos
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
2.8K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.8K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
431
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
431
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
513
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
513
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
166
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
166
01:16Antianginal Drugs: Nitrates and β-Blockers
590
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
590
01:27Regulation of the Cardiovascular System
1.1K
The regulation of the cardiovascular system allows the body to adapt to various demands and maintain homeostasis.
The regulation of the cardiovascular system involves the autonomic nervous system (ANS), baroreceptors, and chemoreceptors, ensuring that heart rate and blood pressure are appropriately modulated in response to varying physiological demands.
The ANS comprises two main divisions: the sympathetic and parasympathetic nervous systems. The sympathetic nervous system enhances...
The regulation of the cardiovascular system involves the autonomic nervous system (ANS), baroreceptors, and chemoreceptors, ensuring that heart rate and blood pressure are appropriately modulated in response to varying physiological demands.
The ANS comprises two main divisions: the sympathetic and parasympathetic nervous systems. The sympathetic nervous system enhances...
1.1K